Company news
Aytu BioPharma, Inc. news in 2019
Aytu BioPharma, Inc.'s news releases, calls and decks from 2019, newest first.
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
December 23, 2019
Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals
December 1, 2019
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary
November 18, 2019
Aytu Reports First Quarter 2020 Financial Results
November 13, 2019
Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations
November 10, 2019
Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update
November 6, 2019
Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase
November 3, 2019
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary
October 20, 2019
Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
October 16, 2019
Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
October 15, 2019
Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
October 13, 2019
Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market
October 1, 2019
Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019
September 25, 2019
Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives
September 23, 2019
Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals
September 11, 2019
Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa
September 9, 2019
Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals
September 3, 2019